Review
Medicine, Research & Experimental
Jiajing Sun, Sikai Wu, Zixian Jin, Sijia Ren, William C. Cho, Chengchu Zhu, Jianfei Shen
Summary: Lung cancer has high morbidity and mortality rates, with tumor metastasis being a significant risk factor for death. Even after complete removal of a tumor at an early stage, there is still a risk of recurrence. Lymph node micrometastasis has been found to be associated with poor prognosis, but predicting prognosis and choosing the appropriate surgical and postoperative adjuvant chemotherapy options remain challenging for clinicians.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
Michal Benej, Thomas Klikovits, Tibor Krajc, Tomas Bohanes, Lisa Schulte, Maximilian Johannes Hochmair, Stefan Watzka, Berta Mosleh, Konrad Hoetzenecker, Clemens Aigner, Mir Alireza Hoda, Michael Rolf Mueller
Summary: This study evaluated the prognostic value of the lymph node log-odds ratio (LN-LOR) in operable non-small cell lung cancer (NSCLC). The results showed that LN-LOR is significantly associated with overall survival and might better reflect the biological behavior of the disease.
Article
Oncology
Nikhil P. Mankuzhy, Muayad F. Almahariq, Zaid A. Siddiqui, Andrew B. Thompson, Inga S. Grills, Thomas M. Guerrero, Kuei C. Lee, Craig W. Stevens, Thomas J. Quinn
Summary: The role of postoperative radiation therapy for locally advanced lung cancer is controversial, but this study found that it improved overall survival for a subset of patients with a high positive to sampled lymph node ratio.
CLINICAL LUNG CANCER
(2021)
Article
Medicine, General & Internal
Xiang Zhang, Nan Feng, Bo Wu, Yiping Wei, Wenxiong Zhang
Summary: Lymph node ratio (LNR) is an important prognostic indicator in non-small-cell lung cancer (NSCLC), with higher LNR indicating worse prognosis. This study found that LNR and positive node category have predictive value for prognosis in stage III NSCLC patients.
Article
Oncology
Yuki Shimizu, Terumoto Koike, Toshiki Hasebe, Masaya Nakamura, Tatsuya Goto, Shin-ichi Toyabe, Masanori Tsuchida
Summary: This study aimed to investigate the risk factors for poor postoperative survival and recurrence in patients with NSCLC and nodal metastasis who were surgically treated and did not receive any induction treatments. Multiple-node metastases are risk factors for both poor survival and recurrence. Additional perioperative therapies may be required, especially in patients with squamous cell carcinoma.
Article
Surgery
Yuehui Liang, Qinghong Jian, Ming-Gang Deng, Zongbi Yi, Chan Peng, Chunsheng Lu, Huan Yang, Jinyi Liu
Summary: This study evaluated lymph node ratio (LNR) as a predictor of postoperative radiotherapy (PORT) benefit in esophageal cancer patients. The results showed that LNR exceeding 0.23 was negatively associated with prognosis, and PORT was beneficial only in N1 stage with higher LNR.
ASIAN JOURNAL OF SURGERY
(2023)
Review
Oncology
Paul Van Houtte, Luigi Moretti, Florian Charlier, Martine Roelandts, Dirk Van Gestel
Summary: Preoperative and postoperative radiotherapy with or without chemotherapy has been used in NSCLC for decades, with many unanswered questions despite advancements in knowledge, technology, and surgery. This review summarizes current understanding and discusses unresolved issues in the field.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Review
Surgery
Lei Peng, Qian-Wen Shang, Han-Yu Deng, Zhen-Kun Liu, Wen Li, Yun Wang
Summary: Lymph node dissection is an important part of surgical treatment for early-stage non-small cell lung cancer (NSCLC). Lobectomy with systematic lymph node dissection (SLND) is currently the gold standard surgical treatment for early-stage NSCLC patients. However, lobe-specific lymph node dissection (L-SLND) has been shown to be an alternative therapy for carefully selected patients with early-stage NSCLC. This literature review summarizes the role of L-SLDN in treating early-stage NSCLC and aims to provide evidence for its application.
ASIAN JOURNAL OF SURGERY
(2023)
Article
Oncology
Jian-Xun Chen, Ting-Yu Lu, Yu-Sen Lin, Hsin-Yuan Fang, Pin-Keng Shih
Summary: This study evaluates the impact of PET/CT on tumor recurrence in pN0 NSCLC patients with tumor less than 4 cm, indicating that the presence of positive lymph nodes on PET/CT scans is associated with a higher risk of recurrence. Factors such as tumor SUVmax, positive lymph nodes on PET/CT, and tumor differentiation are significant in predicting tumor recurrence in this patient population.
Article
Medicine, General & Internal
Mariano Provencio, Ernest Nadal, Jose L. Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabe, Joaquim Bosch-Barrera, Joaquin Casal-Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemi Reguart, Javier de Castro, Joaquin Mosquera, Manuel Cobo, Andres Aguilar, Guillermo Lopez Vivanco, Carlos Camps, Rafael Lopez-Castro, Teresa Moran, Isidoro Barneto, Delvys Rodriguez-Abreu, Roberto Serna-Blasco, Raquel Benitez, Carlos Aguado de la Rosa, Ramon Palmero, Florentino Hernando-Trancho, Javier Martin-Lopez, Alberto Cruz-Bermudez, Bartomeu Massuti, Atocha Romero
Summary: This study evaluated the efficacy of the neoadjuvant nivolumab plus chemotherapy regimen on operable stage III non-small-cell lung cancer (NSCLC) patients. The results showed that patients receiving the combination therapy had a higher rate of pathological complete response and longer survival, indicating the effectiveness of this treatment approach in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Jonathan Khalifa, Noemie Thebault, Clara-Maria Scarlata, Emma Norkowski, Carole Massabeau, Laurent Brouchet, Sophie Peries Bataille, Christelle Casaroli, Liza Vaz, Carine Valle, Emeline Sarot, Nathalie Saint-Laurent, Etienne Martin, Pierre-Benoit Pages, Alice Milliere, Julien Mazieres, Elizabeth Cohen-Jonathan Moyal, Francoise Lauzeral-Vizcaino, Maha Ayyoub
Summary: This retrospective study aimed to assess the immune and biological changes in non-involved tumor draining lymph nodes (TDLNs) during node-sparing concurrent chemoradiotherapy (CRT) of non-small cell lung cancer (NSCLC) patients. By analyzing gene expression, significant differences were observed between the CRT+ and CRT- groups. Gene sets associated with antitumor immune response, inflammatory response, and other pathways were enriched in the CRT+ group.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Shinkichi Takamori, Takefumi Komiya, Emily Powell
Summary: The study suggests that performing at least 3 lymph node dissections can improve overall survival in early-stage SCLC patients who undergo lobectomy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Lu Han, Hui Jia, Pingping Song, Xibin Liu, Zhendan Wang, Dujian Zhang
Summary: This study found that lobar lymph node metastasis is common in patients with lung cancer, while lymph node metastasis in non-tumor-bearing segments is rare. Age, differentiation, and the status of lymph nodes found on CAT scan are independent risk factors for lobar lymph node involvement. Further investigation is needed to determine the necessity of lymph node dissection in non-tumor-bearing segments.
FRONTIERS IN MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Brooks Udelsman, David C. Chang, Daniel J. Boffa, Henning A. Gaissert
Summary: This study investigated adherence to guidelines regarding lymph node sampling during lobectomy for non-small cell lung cancer (NSCLC), and its association with hospital lobectomy volume. The results showed that the average rate of >= 10 lymph nodes harvested per lobectomy was higher in medium- to high-volume hospitals. However, 25% of high-volume hospitals still had a lymph node yield of <10 nodes, which may lead to inaccurate staging and have implications for adjuvant therapy and long-term survival.
ANNALS OF THORACIC SURGERY
(2023)
Article
Medicine, General & Internal
Lei Bi, Hong Zhang, Mingjian Ge, Zhongzhu Lv, Yiping Deng, Tenghao Rong, Chaolun Liu
Summary: The study investigated the necessity of dissecting intrapulmonary lymph nodes in peripheral non-small cell lung cancer and the metastatic pattern of the lymph nodes. The findings suggest that dissecting stations 13 and 14 may be helpful for identifying lymph node metastasis and accurately staging primary NSCLC.
Meeting Abstract
Oncology
E. Ofek, J. Bar, A. Zer, C. Mayer, C. Sade Zaltz, L. Litzky, C. J. Langer, C. Davis, C. Solomides, I. Micaily, J. M. Johnson, R. Stapp, Z. L. Quinn, Z. Rachmiel, A. Laniado, M. Matalon, E. Markovits, O. Zelichov, M. Feinmesser, I. Barshack
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Nicolas Girard, Jair Bar, Pilar Garrido, Marina C. Garassino, Fiona McDonald, Francoise Mornex, Andrea R. Filippi, Hans J. M. Smit, Solange Peters, John K. Field, Daniel C. Christoph, Anne Sibille, Rainer Fietkau, Vilde D. Haakensen, Christos Chouaid, Ben Markman, T. Jeroen N. Hiltermann, Alvaro Taus, William Sawyer, Allison Allen, Pratibha Chander, Muriel Licour, Benjamin Solomon
Summary: This study analyzed the treatment characteristics and real-world progression-free survival (rwPFS) of patients receiving durvalumab, and the results showed that in patients with advanced lung cancer, rwPFS was longer in patients who received concurrent chemoradiotherapy and in patients with higher programmed cell death-ligand 1 expression.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Shira Sagie, Nitzan Maixner, Amos Stemmer, Anastasiya Lobachov, Jair Bar, Damien Urban
Summary: This study provides evidence for the efficacy of immunotherapy in the first-line treatment of extensive-stage small cell lung cancer (SCLC) in a real-world setting. The addition of immunotherapy to the treatment protocol may benefit even some patients not included in randomized clinical trials (RCTs), such as those with poor performance status (PS).
Article
Oncology
Lavinia Tan, Ben Tran, Jeanne Tie, Ben Markman, Sumi Ananda, Niall C. Tebbutt, Michael Michael, Emma Link, Stephen Q. Wong, Sushma Chandrashekar, Jerick Guinto, David Ritchie, Rachel Koldej, Benjamin J. Solomon, Grant A. McArthur, Rodney J. Hicks, Peter Gibbs, Sarah-Jane Dawson, Jayesh Desai
Summary: BRAF V600E mutant metastatic colorectal cancer is a significant clinical problem. Combination therapy with vemurafenib and small-molecule EGFR inhibitors has shown effectiveness in pre-clinical studies, but clinical investigation is lacking.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Oncology
Benjamin J. Solomon, Todd M. Bauer, Tony S. K. Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylan Lopez Lopez, Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip
Editorial Material
Oncology
Trudy C. Wu, Annalise Stube, Carol Felix, Denise Oseguera, Tahmineh Romero, Jonathan Goldman, Edward B. Garon, Jay M. Lee, John Glaspy, Aaron E. Lisberg, Chad G. Rusthoven, D. Ross Camidge, Shankar Siva, Benjamin Solomon, Alan Lee, Stephen E. Tenn, Narek Shaverdian, Michael L. Steinberg, Ann C. Raldow, Percy Lee
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Letter
Oncology
Nicolas Girard, Marina C. Garassino, Benjamin Solomon
JOURNAL OF THORACIC ONCOLOGY
(2023)
Letter
Oncology
Nicolas Girard, Marina C. Garassino, Benjamin Solomon
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Ross A. Soo, Jean-Francois Martini, Anthonie J. van der Wekken, Shunsuke Teraoka, Roberto Ferrara, Alice T. Shaw, Deborah Shepard, Anna Maria Calella, Anna Polli, Francesca Toffalorio, Pascale Tomasini, Chao-Hua Chiu, Dariusz M. Kowalski, Hye Ryun Kim, Benjamin J. Solomon
Summary: In treatment-naive patients with advanced ALK-positive NSCLC, ctDNA can be used as a biomarker to predict the efficacy of lorlatinib treatment.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Medicine, General & Internal
Adrianus Johannes de Langen, Melissa L. Johnson, Julien Mazieres, Anne -Marie C. Dingemans, Giannis Mountzios, Miklos Pless, Jurgen Wolf, Martin Schuler, Herve Lena, Ferdinandos Skoulidis, Yasuto Yoneshima, Sang-We Kim, Helena Linardou, Silvia Novello, Anthonie J. van der Wekken, Yuanbin Chen, Solange Peters, Enriqueta Felip, Benjamin J. Solomon, Suresh S. Ramalingam, Christophe Dooms, Colin R. Lindsay, Carlos Gil Ferreira, Normand Blais, Cynthia C. Obiozor, Yang Wang, Bhakti Mehta, Tracy Varrieur, Gataree Ngarmchamnanrith, Bjorn Stollenwerk, David Waterhouse, Luis Paz-Ares
Summary: This study compared the efficacy and safety of Sotorasib with standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation. The results showed that compared to docetaxel, Sotorasib significantly increased progression-free survival and had a more favorable safety profile.
Article
Oncology
Sameh Daher, Alona Zer, Roi Tschernichovsky, Rinat Yacobi, Iris Barshack, Shani Tsabari, Yakir Rottenberg, Aviad Zick, Teodor Gottfried, Anastasiya Lobachov, Edith M. Marom, Damien Urban, Akram Saad, Hadas Gantz-Sorotsky, Amir Onn, Jair Bar
Summary: This study found that PIK3CA mutations can be targeted for treatment in non-small cell lung cancer patients. One patient with a PIK3CA mutation was treated with a PI3Ka-isoform selective inhibitor BYL719 (Alpelisib), and showed significant improvement.
Review
Oncology
Grace Chazan, Benjamin J. Solomon
Summary: First-line treatment options for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbour anaplastic lymphoma kinase (ALK) gene rearrangements have evolved rapidly. Although newer generation ALK inhibitors have demonstrated superiority to crizotinib, head-to-head clinical trials comparing these inhibitors are lacking. Decisions on optimal first-line treatment must be based on analysis of relevant trials and consideration of various factors.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Meeting Abstract
Oncology
E. Dudnik, A. Raphael, L. Holtzman, J. Dudnik, D. Urban, W. Kian, A. Cohen, M. Moskovitz, A. Zer, J. Bar, N. Maimon Rabinovich, S. Grynberg, C. Oedegaard, A. Agbarya, N. Peled, T. Shochat, A. Onn
JOURNAL OF THORACIC ONCOLOGY
(2022)
Meeting Abstract
Oncology
O. Illini, H. Fabikan, A. Swalduz, D. Krenbek, A. Vikstrom, M. Schumacher, E. Dudnik, M. Studnicka, R. Ohman, R. Wurm, L. Wannesson, N. Peled, W. Kian, J. Bar, S. Daher, A. Addeo, O. Rotem, G. Pall, A. Zer, A. Saad, T. Cufer, H. G. Sorotsky, S. M. S. Hashemi, K. Mohorcic, R. Stoff, Y. Rovitsky, S. Keren-Rosenberg, T. Winder, C. Weinlinger, A. Valipour, M. J. Hochmair
JOURNAL OF THORACIC ONCOLOGY
(2022)
Review
Medicine, General & Internal
L. B. Cameron, N. Hitchen, E. Chandran, T. Morris, R. Manser, B. J. Solomon, V Jordan
Summary: This study evaluated the safety and efficacy of ALK inhibitors as monotherapy for advanced ALK-rearranged NSCLC. The results showed that ALK inhibitors are effective in improving progression-free survival, overall survival, and overall response rate, with minimal adverse events compared to chemotherapy. Next-generation ALK inhibitors are more effective and safe than first-generation ALK inhibitors. However, further research is needed to compare different next-generation ALK inhibitors.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)